Press Releases

Citius Announces United States Patent & Trademark Office Registered the Company's Mino-Lok® Trademark

CRANFORD, N.J., June 19, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("CITIUS") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company, announced that Mino-Lok® is now a registered trademark with the U.S. Patent and Trademark Office.  Citius' Mino-Lok® product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). CRBSIs are very serious, especially in cancer patients receiving therapy through central venous catheters (CVCs), and in hemodialysis patients where venous access presents a challenge.

Citius' Mino-Lok® product is intended to salvage the CVC obviating the need to remove and replace the catheter.  This is a recognized unmet medical need. There are no alternatives other than the removal and reinsertion of the CVC once the CVC becomes infected. Studies show that removal and reinsertion of CVCs have a 15 to 20% complication rate, including pneumothorax, misplacement, and arterial puncture.

"We are working towards FDA approval and commercialization of Mino-Lok, We are currently conducting a Phase 3 clinical trial and are treating patients with Mino-Lok compared to standard antibiotic lock therapies," said Mr. Myron Holubiak, CEO of Citius.  "Hopefully, we will be able to complete our trial next year and begin the NDA review process. Mino-Lok has been granted "Fast Track" status by the FDA for this development program."

The Company's Mino-Lok® product contains a proprietary combination of minocycline, edetate (disodium EDTA), and ethyl alcohol, all of which act synergistically to break down bacterial biofilms, eradicate the bacteria, provide anti-clotting properties to maintain patency in CVCs, and salvage the indwelling catheter. The Mino-Lok™ product is used in two-hour locking cycles allowing the CVC to be used for its intended purposes for the remaining 22 hours each day.

Mino-Lok® is under investigation and not approved for commercial use.

About Citius Pharmaceuticals, Inc.
Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives, cancer care and unique prescription products using innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients.  We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs.  By using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. We focus on developing products that have intellectual property protection and competitive advantages to existing therapeutic approaches. www.citiuspharma.com

Safe Harbor
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius.  You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks relating to the results of research and development activities, including the risk that preclinical results might not be replicated in any subsequent studies or trials and are not indicative of success in clinical trials; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks related to our growth strategy; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; and other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. 

Contact:
Andrew Scott                                                                                    
Vice President, Corporate Development                                                                                              
908-967-6677
ascott@citiuspharma.com

Cision View original content:http://www.prnewswire.com/news-releases/citius-announces-united-states-patent--trademark-office-registered-the-companys-mino-lok-trademark-300667877.html

SOURCE Citius Pharmaceuticals, Inc.